Advertisement

Search Results

Advertisement



Your search for all items matches 28305 pages

Showing 1 - 50


gynecologic cancers

Pedro T. Ramirez, MD, on Hysterectomy for Early Cervical Cancer: New Findings on Open vs Minimally Invasive Surgery

Pedro T. Ramirez, MD, of The University of Texas MD Anderson Cancer Center, discusses the final analysis of the LACC trial (Laparoscopic Approach to Cervical Cancer), which showed that women with early cervical cancer who need a radical hysterectomy may have worse outcomes with minimally invasive...

gynecologic cancers

Ursula A. Matulonis, MD, on Ovarian Cancer: New Data on Mirvetuximab Soravtansine

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses findings from the SORAYA study on the efficacy and safety of mirvetuximab soravtansine in patients who have platinum-resistant ovarian cancer with high folate receptor–alpha expression. Based on the results, Dr. Matulonis believes...

solid tumors
genomics/genetics

PARP1-Selective Inhibitor Offers Significant Benefits Over Older Predecessors in Treatment of Solid Tumors

The first-in-human, first-in-class trial of the next-generation PARP (poly [ADP-ribose] polymerase) 1–selective inhibitor AZD5305 suggests this drug may be a welcome advance over its U.S. Food and Drug Administration (FDA)-approved predecessors in the treatment of solid tumors with alterations in...

gastroesophageal cancer
covid-19

Delays in Surgery for Advanced Esophageal Cancer Result in Significantly Worse Survival

Delays in surgery for esophageal cancer did not appear to have much impact on patients’ relative survival for early-stage cancer compared with patients who had surgery early, but they did reduce the relative survival rate by almost half for patients with more advanced disease, according to an...

colorectal cancer

Age at Initiation of Colorectal Cancer Screening and Risk of Colorectal Cancer Among U.S. Women

In a study reported in JAMA Oncology, Ma et al found that the initiation of lower gastrointestinal endoscopy screening in women younger than age 50 was associated with a reduced risk of colorectal cancer vs no screening, and a greater absolute risk reduction compared with screening starting at age...

lymphoma
immunotherapy

Report Investigates Potential Causes of Decreasing Responses to CAR T-Cell Therapy in Patients With Non-Hodgkin Lymphoma

A study published by Jackson et al in Cancer Discovery investigated the reasons for decreased remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor (CAR) T-cell therapy. "CAR T-cell therapy is a promising treatment for non-Hodgkin lymphoma, especially for...

colorectal cancer

Watch-and-Wait Strategy for Organ Preservation in Patients Receiving Total Neoadjuvant Therapy for Rectal Adenocarcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Garcia-Aguilar et al found that total neoadjuvant therapy followed by a watch-and-wait strategy vs total mesorectal excision based on response allowed for organ preservation in approximately half of patients with rectal...

leukemia
survivorship

AYA Leukemia Survivors Have Higher Mortality Rates Than the General Population

Although considered a rare occurrence in adolescents and young adults (AYAs), aged 15 to 39 years, the incidence of cancer in this age group has been increasing by approximately 30% since the 1970s. This year, it is estimated that nearly 90,000 new cases of cancer will be diagnosed in this...

MONALEESA-3: Updated Overall Survival Analysis

On this episode, we’ll be discussing an updated overall survival analysis from the MONALEESA-3 trial presented at the ESMO Breast Cancer Congress 2022. Then, we’ll hear from a researcher about the current state of cancer research and anticipated trends in the field.

issues in oncology
genomics/genetics

Nickolas Papadopoulos, PhD, on Multicancer Early Detection: Opportunities and Challenges

Nickolas Papadopoulos, PhD, of the Sidney Kimmel Comprehensive Cancer Center, discusses early detection as the key to reducing cancer mortality and the lack of tests for many malignancies. Liquid biopsies have the potential to screen for various tumor types, albeit with varying levels of...

issues in oncology
survivorship

Maria Alma Rodriguez, MD, on Vaccinations for Patients With Cancer and Cancer Survivors

Maria Alma Rodriguez, MD, of The University of Texas MD Anderson Cancer Center, discusses the need for various types of vaccinations in patients with cancer, who are vulnerable to infection while under active treatment and whose immune deficits may persist long after treatment is finished. Dr....

prostate cancer

Polygenic Score May Enable More Precise PSA Screening for Prostate Cancer

The use of a polygenic score incorporating variations in prostate-specific antigen (PSA) values that are not due to cancer may allow for more precise PSA screening, according to findings of a large genome-wide association study presented at the American Association for Cancer Research (AACR) Annual ...

hematologic malignancies
multiple myeloma
lymphoma
leukemia

Prevalence of Plasma Cell and Lymphoproliferative Disorders in Relatives of Probands With Light Chain Amyloidosis

In a study reported in the British Journal of Haematology, Staron et al found that the prevalence of plasma cell and lymphoproliferative disorders among blood relatives of probands with light chain (AL) amyloidosis was low overall and varied according to proband AL amyloidosis subtype. Despite...

colorectal cancer

3 vs 6 Months of Adjuvant Oxaliplatin- and Fluoropyrimidine-Based Therapy for Stage III Colon Cancer: Final Analysis

As reported in the Journal of Clinical Oncology by Yoshino et al, the final analysis of survival and safety of the Japanese phase III ACHIEVE trial (part of the IDEA Collaboration) has shown no difference in disease-free or overall survival with 3 vs 6 months of adjuvant mFOLFOX6 (fluorouracil,...

bladder cancer

Mortality and Perioperative Outcomes With Open vs Robot-Assisted Radical Cystectomy for Bladder Cancer

In a Swedish population-based cohort study reported in JAMA Network Open, Mortezavi et al found that robot-assisted radical cystectomy with intracorporeal urinary diversion was associated with reduced all-cause mortality, reduced high-grade complications, and improved perioperative outcomes vs open ...

solid tumors

Association of Chromosome 3p25.3 Gain With Cisplatin Resistance and Outcomes in Male Malignant Germ Cell Tumors

In a study reported in the Journal of Clinical Oncology, Timmerman et al found that chromosome 3p25.3 gain was present in all cisplatin-resistant germ cell tumor (GCT) lines in vitro; was more common in patients with relapsed or cisplatin-resistant male type II GCTs; and was associated with poorer...

lung cancer

Patients With NSCLC Brain Metastases Undergoing Neurosurgical Resection: Comparison of Treatment Regimens

In a German single-institution retrospective cohort study reported in JAMA Network Open, Wasilewski et al found that treatment with immune checkpoint inhibition plus radiotherapy was associated with prolonged overall survival vs platinum-based chemotherapy plus radiotherapy in patients with brain...

lung cancer

Ara Klijian, MD, on Lung Cancer: Operability in Patients With Poor Pulmonary Function

Ara Klijian, MD, of Scripps Health, discusses findings on the safety of AVATS (awake video-assisted thoracic surgery), a procedure that may benefit select patients, including those whose early non–small cell lung cancer was previously deemed inoperable due to poor pulmonary function. Performed...

breast cancer

Sentinel Node May Not Be Informative in Making Treatment Decisions for Some Breast Cancer Subsets

In women aged 70 and older with hormone receptor–positive, HER2-negative, low-risk breast cancers, sentinel lymph node biopsy may not be a reliable indicator of the need for adjuvant chemotherapy, researchers reported at the 2022 American Society of Breast Surgeons Annual Meeting.1 “We found that...

issues in oncology
supportive care

New Research Encourages Harnessing Health Technology to Help Patients With Cancer Quit Smoking

New research published by Ramsey et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that the inclusion of the smoking cessation tool Electronic Health Record–Enabled Evidence-Based Smoking Cessation Treatment (ELEVATE) into electronic health records may increase...

skin cancer
immunotherapy

Anti–CTLA-4 Antibody–Based Treatment in Patients With Metastatic Melanoma Experiencing Disease Progression on Relatlimab/Nivolumab

In a study reported as a letter to the editor in The New England Journal of Medicine, Alexander M. Menzies, MD, and colleagues found that patients with metastatic melanoma who had progressive disease while receiving relatlimab/nivolumab had poor responses to anti–CTLA-4–based treatment. As noted...

immunotherapy

Report Finds Targeting IL-6 May Help to Relieve Immunotherapy Side Effects

Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events caused by immunotherapy by targeting the cytokine interleukin-6 (IL-6). The study, published by Hailemichael et al in Cancer Cell, establishes a proof of concept ...

immunotherapy
hematologic malignancies
leukemia
lymphoma

Rehospitalization and Emergency Department Visits After CAR T-Cell Therapy in Commercially Insured Patients With Cancer

In a single-institution study reported in a research letter in JAMA Oncology, Kenzik et al found substantial rates of rehospitalization and emergency department visits after chimeric antigen receptor (CAR) T-cell therapy among commercially insured patients with cancer. Study Details The study...

hepatobiliary cancer
pancreatic cancer
immunotherapy
genomics/genetics

Ipilimumab/Nivolumab in Patients With Metastatic Pancreatic or Biliary Cancer and HRD Pathogenic Germline Variants

In a single-institution case series reported in a research letter in JAMA Oncology, Terrero et al found that the combination of ipilimumab and nivolumab was active in patients with chemotherapy-refractory metastatic pancreatic or biliary cancer with homologous recombination deficiency (HRD)...

lung cancer

Beyond Immunotherapy: New Targeted Agents for Advanced NSCLC

The advent of PD-1 and PD-L1 checkpoint inhibitors has changed the treatment landscape of advanced non–small cell lung cancer (NSCLC), but only approximately 20% of patients treated with immunotherapy will be alive at 5 years. According to Melissa L. Johnson, MD, Director, Lung Cancer Research,...

pancreatic cancer
genomics/genetics

Christine A. Iacobuzio-Donahue, MD, PhD, on Pancreatic Cancer: Novel Insights Into Genetics and Evolution

Christine A. Iacobuzio-Donahue, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses her research on the evolutionary features of advanced stage pancreatic cancers and the insights that may be used to help improve patient outcomes (Abstract PL05).

cns cancers

ASTRO Issues Clinical Guideline on Radiation Therapy for Brain Metastases

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat patients with brain metastases. Evidence-based recommendations guide the multidisciplinary planning and delivery of advanced radiation therapy techniques to...

colorectal cancer

Comparison of 2020 NICE Criteria for Preoperative Radiotherapy in Rectal Cancer Treated by Surgery Alone With Established MRI Prognostic Factors

In a retrospective cohort study reported in The Lancet Oncology, Lord et al found that high-risk patients with rectal cancer treated with surgery alone who were more likely to benefit from preoperative radiotherapy were better selected using proven magnetic resonance imaging (MRI) prognostic...

gynecologic cancers

Trends in Hysterectomy-Corrected Uterine Cancer Mortality and Racial/Ethnic Differences

In a study reported in JAMA Oncology, Clarke et al found that hysterectomy-corrected rates of mortality from uterine corpus cancer overall and from nonendometrioid carcinomas have increased in recent years, with mortality rates being highest in Black women. The study involved data from the U.S....

breast cancer

Addition of Ibandronate to Adjuvant Endocrine Therapy in Postmenopausal Women With ER-Positive Breast Cancer

In the Dutch phase III TEAM-IIB trial reported in the Journal of Clinical Oncology, Sonja B. Vliek, MD, and colleagues found that the addition of oral ibandronate to adjuvant endocrine therapy did not improve disease-free survival in postmenopausal women with estrogen receptor (ER)-positive stage I ...

gastroesophageal cancer
immunotherapy

Second-Line Tislelizumab vs Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

In the phase III RATIONALE-302 trial reported in the Journal of Clinical Oncology, Shen et al found that the anti–PD-1 antibody tislelizumab significantly improved overall survival vs chemotherapy in the second-line treatment of patients with advanced or metastatic esophageal squamous cell...

breast cancer

Why Are Black Women Still Dying at Higher Rates Than White Women From Breast Cancer?

What is so dismaying to me is that the statistic on survival for Black women with breast cancer has not changed since I was diagnosed with breast cancer 17 years ago. In 2005, Black women were 41% more likely to die of the disease than White women, even though Black women are less likely to be...

issues in oncology
survivorship

Short and Shorter Screening Tools for Food Insecurity

A survey of oncology registered dietitian nutritionists (RDNs)1 found that most of those surveyed were not using a validated assessment tool to identify food insecurity but expressed interest in obtaining the Six-Item Short Form of the Food Security Survey Module.2  The six-item food insecurity...

issues in oncology
survivorship

Assessing Food Insecurity Among Patients With Cancer

Food insecurity, particularly as it affects cancer survivors, is a serious problem, according to a survey of oncology registered dietitian nutritionists (RDNs) published in the Journal of the Academy of Nutrition and Dietetics.1 “Despite these concerns, most oncology RDNs interviewed are not using...

integrative oncology

Music Interventions for Improving Psychological and Physical Symptoms in People With Cancer

Guest Editor’s Note: Cancer and its treatments are associated with both physical and psychological symptoms that can have substantial impact on patients’ quality of life. Music therapy is a complementary modality that is being increasingly used for cancer symptom management. In this article, Joke...

lymphoma

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...

From a Small Village in China to Cutting-Edge Clinical Cancer Research for Cynthia X. Ma, MD, PhD

Cynthia X. Ma, MD, PhD, was born in a small village in Hebei, a province in the Central China region. “I grew up in a poor village with less than 1,000 people. We had no medical services in our village, so we had to travel to the city to see a doctor, which was quite some distance away. In the...

lung cancer
genomics/genetics
immunotherapy

DESTINY-Lung01: Is Trastuzumab Deruxtecan the Answer for HER2-Mutant Lung Cancer?

The human epidermal growth factor (HER) family of receptors are a well-established therapeutic target. Indeed, seminal studies conducted nearly 2 decades ago identified a key association between activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR, also known as...

lung cancer
genomics/genetics
immunotherapy

DESTINY-Lung01: T-DXd Shows Durable Activity in Previously Treated Metastatic HER2-Mutant NSCLC

In a phase II trial (DESTINY-Lung01) reported in The New England Journal of Medicine, Bob T. Li, MD, PhD, MPH, of the Thoracic Oncology and Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York, and colleagues found that fam-trastuzumab deruxtecan-nxki (T-DXd) showed...

MSK Introduces The Starr Foundation Program for Discovery Science

Memorial Sloan Kettering Cancer Center (MSK) recently announced the establishment of The Starr Foundation Program for Discovery Science, a pioneering initiative made possible by a $50 million gift from The Starr Foundation. The program will support the work of scientists at the Sloan Kettering...

ASCO Honors 2022 Special Awards Recipients

ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2022 ASCO Annual Meeting in Chicago. Hear from select award...

Expert Point of View: Barbara S. Norquist, MD

Discussant of the PRIME trial, Barbara S. Norquist, MD, Associate Professor of Obstetrics and Gynecology at the University of Washington, Seattle, noted that although all subgroups in the PRIMA study appeared to derive benefit from niraparib maintenance therapy, patients with homologous...

gynecologic cancers

PRIME Trial: Niraparib Maintenance Therapy Improves Progression-Free Survival in Advanced Ovarian Cancer

A larger population of patients with newly diagnosed advanced ovarian cancer may be able to benefit from niraparib maintenance therapy, with an improved safety profile, according to phase III data presented at the 2022 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.1 Results ...

breast cancer

Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer

In an updated analysis of the phase III MONALEESA-3 trial, which included postmenopausal patients with advanced/metastatic hormone receptor (HR)-positive, HER2-negative breast cancer, first-line treatment with ribociclib plus fulvestrant lengthened overall survival by approximately 16 months vs...

breast cancer
immunotherapy

TUXEDO-1: Efficacy of T-DXd for Patients With HER2-Positive Breast Cancer and Active Brain Metastases

In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...

NCCN Announces Indiana University Melvin and Bren Simon Comprehensive Cancer Center Joins Member Institutions

The National Comprehensive Cancer Network® (NCCN®) recently announced that Indiana University Melvin and Bren Simon Comprehensive Cancer Center has joined the not-for-profit alliance of leading cancer centers as the 32nd member institution. NCCN was founded by 13 original Member Institutions in...

Penn Medicine Appoints Robert Vonderheide, MD, DPhil, to Second 5-Year Term as Director of Abramson Cancer Center

Robert H. Vonderheide, MD, DPhil, has been appointed to a second 5-year term as Director of the Abramson Cancer Center (ACC) at the University of Pennsylvania, following a highly successful tenure that saw 17 U.S. Food and Drug Administration approvals in oncology for therapies based on studies...

David Braun, MD, PhD, Joins Prostate and Urologic Cancers Program at Yale Cancer Center

Yale Cancer Center and Smilow Cancer Hospital welcome David Braun, MD, PhD, Assistant Professor of Medicine (Medical Oncology) and a member of the Center for Molecular and Cellular Oncology (CMCO). Dr. Braun cares for patients with kidney cancer. Dr. Braun received his PhD in Computational Biology ...

Sam Mbulaiteye, MBChB, MPhil, MMed, Named 2022 Scientist of the Year by Lymphoma Foundation of America

Sam Mbulaiteye, MBChB, MPhil, MMed, senior investigator in the Infections and Immunoepidemiology Branch, in the Division of Cancer Epidemiology & Genetics of the National Cancer Institute, was recently recognized by the Lymphoma Foundation of America with its 2022 Scientist of the Year Award....

J. Paul Taylor, MD, PhD, Named Scientific Director and Executive Vice President of St. Jude

J. Paul Taylor, MD, PhD, has been named Scientific Director and Executive Vice President of St. Jude Children’s Research Hospital. Dr. Taylor steps into the role during a pivotal time of growth for the hospital. Under its $11.5 billion, 6-year strategic plan, the institution’s scientific...

Advertisement

Advertisement



Advertisement